Clinical and pressure-flow changes after long-term treatment with alfuzosin SR

Urologia Internationalis

Volumn 71, Issue 1, 2003, Pages 31-36

  De Nunzio, Cosimo ^a,b   Franco, G ^a   Iori, F ^a   Leonardo, C ^a   Minardi, V ^a   Laurenti, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

1 Antagonist; Alfuzosin; Benign prostatic hyperplasia; Prostate; Urodynamics

Indexed keywords

ALFUZOSIN;

ADULT; AGED; ALGORITHM; ARTICLE; BLADDER CAPACITY; BLADDER NECK STENOSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; EVALUATION; FOLLOW UP; HUMAN; KRUSKAL WALLIS TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MICTURITION; ORGAN SIZE; PRESSURE AND TENSION; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; RESIDUAL URINE; SCORING SYSTEM; STATISTICAL ANALYSIS; TREATMENT OUTCOME; URINARY TRACT DISEASE; URINARY TRACT OBSTRUCTION; URINE FLOW RATE; URINE VOLUME; URODYNAMICS; WILCOXON SIGNED RANKS TEST;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; QUINAZOLINES; TIME FACTORS; URINARY BLADDER NECK OBSTRUCTION; URODYNAMICS;

EID: 0037971740     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071090     Document Type: Article

References (20)

1. McNeal J: Pathology of benign prostatic hyperplasia: Insight into etiology. Urol Clin North Am 1990;17:477-486.
2. Lepor, M, Williford, WO, Barry, MJ, et al: The impact of medical therapy on bother due to symptoms, quality of life and global outcome on factors predicting response. Veterans Affairs Co-operative Studies: Benign prostatic hyperplasia study group. J Urol 1998;164:1358-1367.
3. Caine M: The present role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. J Urol 1986;136:1-4.
4. Gormley GJ, Stoner E, Bruskewitz RC, et al: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride study group. N Engl J Med 1992;327:1185-1191.
5. Kunisawa Y, Kawabe K, Niijime T, et al: A pharmacological study of alpha adrenergic receptor subtypes in smooth muscle of human urinary bladder and prostatic urethra. J Urol 1985;134:396-398.
6. Caine M, Raz S, Ziegler M: Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br Urol 1975;27:193-202.
7. Hedlund H, Anderson KE, Ek A: Effects of prazosin in patients with benign prostatic obstruction. J Urol 1983;130:275-278.
8. Lepor H, Auerbach S, Puras-Baez A, et al: A randomized placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992;148:1467-1474.
9. Janknegt RA, Chapple CR, for the Doxazosin study group: Efficacy and safety of the alpha 1-blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Eur Urol 1993;24:319-326.
10. Jardin A, Bensadoun H, DeLauche-Cavallier MC, et al: Alfuzosin for the treatment of benign prostatic hypertrophy. Lancet 1991;337:1457-1461.
11. Teillac P, Delauche Cavallier MC, Attali P and the DUALF Group: Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. Br J Urol 1992;70:58-64.
12. Jardin A, Bensadoun H, Delauche Cavallier MC, et al: Long term treatment of benign prostatic hyperplasia with alfuzosin. A 24-30 month survey. Br J Urol 1994;74:579-584.
13. Buzeln JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC and the ALGEBI study Group: Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. Eur Urol 1997;21:190-198.
14. Buzelin JM, Herbert M, Blondin P and the PRAZALF group: Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: Comparative study with prazosin. Br J Urol 1993;72:922-927.
15. Abrams P, Buzelin JM, Griffiths D et al: The urodynamic assessment of lower urinary tract symptoms. Proc 4th Int Consult Benign Prostatic Hyperplasia (BPH). Jersey, 1998, pp 323-377.
16. Rossi C, Kortmann BBM, Sonke GS, et al: Alpha-blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it. J Urol 2001;165:38-41.
17. Martorana G, Giberti C, Di Silverio F, et al: Effect of short-term treatment with the alpha-1-blocker alfuzosin on urodynamic pressure-flow parameters in patients with benign prostatic hyperplasia. Eur Urol 1997;32:47-51.
18. Schäfer W: Analysis of bladder-outlet function with the linearized passive urethral resistance relation, linPURR, and a disease-specific approach for grading obstruction: From complex to simple. World J Urol 1995;13:47-58.
19. McNeill S, Hargreave TB, Geffriaud-Ricouard C, et al: Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Pooled analysis of eleven controlled studies with alfuzosin. Urology 2000;57:459-465.
20. Perlberg S, Caine M: Adrenergic response of bladder muscle in prostatic obstruction. Urology 1982;20:524-527.